MySize reports 62% revenue growth in first quarter 2026

MySize posted Q1 2026 revenue of $2.39 million, up 62% year over year, with gross profit rising 124% to $940,000 and gross margin improving to 39.3%. However, operating expenses climbed across the board and net loss widened to $1.48 million from $1.06 million, while cash was only $910,000 at quarter-end. The company also received a Nasdaq bid price deficiency notice after trading below $1.00 for 30 consecutive days, adding delisting risk despite the better top-line growth.

Analysis

MYSZ is now in the classic microcap treadmill: headline growth can coexist with worsening equity value when operating losses, dilution risk, and listing pressure dominate the capital structure. The key second-order issue is not the quarter itself, but whether the company can finance its current burn without issuing stock into sub-$1 price levels, which would further impair liquidity and likely keep any rerating capped. In this setup, strong revenue growth often becomes a value trap because the market discounts quality of growth unless it translates into self-funding cash generation.

The Nasdaq bid-price deficiency creates a binary near-term catalyst, but the probability-weighted outcome still skews negative because compliance usually requires a sustained technical rally rather than fundamental improvement. If management tries to solve the problem with a reverse split, the stock may get past the listing hurdle but often loses incremental retail sponsorship and faces another lower-high/lower-low pattern over the following weeks. The real watch item over the next 30-90 days is whether cash burn forces a financing before compliance, which would likely pressure shares and could accelerate shareholder dilution.

A subtler read-through is that the stronger growth in fashion e-commerce and resale integration could be evidence of a business mix shift toward higher-frequency consumer activity, but the margin improvement is not yet enough to offset fixed overhead. That means competitors with cleaner balance sheets and better working-capital discipline can likely outspend MYSZ on customer acquisition and inventory turns. In other words, the operating story may be improving, but the equity story remains hostage to capital structure and market microstructure rather than demand alone.

Consensus may be underestimating how little fundamental progress is needed to produce a squeeze in a stock this depressed, but that is a tradeable event, not an investable one. The move can overshoot on any reverse-split speculation, partnership announcement, or short-covering burst, yet those rallies are likely to fade unless accompanied by a credible path to positive operating cash flow within the next two quarters.

Key Decisions for Investors

• Avoid initiating a long-only position in MYSZ at current levels; the risk/reward is poor until the company either resolves Nasdaq compliance or shows a credible path to self-funding cash flow over the next 1-2 quarters.
• For event-driven traders, consider a small tactical long only on confirmed reverse-split or compliance-related technical momentum, using a tight 10-15% stop and a 2:1 upside target into any short-covering spike over 5-20 trading days.
• If liquidity allows, express a bearish view via put spreads on MYSZ into any compliance-rally or financing announcement, targeting a 30-50% downside move over 1-3 months if dilution or a reverse split is announced.
• Pair trade idea: long better-capitalized retail/resale operators with cleaner balance sheets versus short MYSZ, to isolate execution quality from microcap financing risk over the next 3-6 months.
• Set a catalyst watch for the next earnings release and any Nasdaq correspondence; if cash falls meaningfully below current levels before compliance, expected equity dilution becomes the highest-probability negative catalyst.